CDK4/6 inhibitors combined with fulvestrant for HR + /HER2 - advanced breast cancer.

Authors :: Zhang J
Hao C
Source :: Translational breast cancer research : a journal focusing on translational research in breast cancer [Transl Breast Cancer Res] 2022 Apr 30; Vol. 3, pp. 10. Date of Electronic Publication: 2022 Apr 30 (Print Publication: 2022).
Publication Year :: 2022
Abstract: Competing Interests: Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tbcr.amegroups.com/article/view/10.21037/tbcr-22-17/coif). CH serves as an unpaid editorial board member of Translational Breast Cancer Research from May 2021 to April 2023. The other author has no conflicts of interest to declare.

Language :: English
ISSN :: 2218-6778
Volume :: 3
Database :: MEDLINE
Journal :: Translational breast cancer research : a journal focusing on translational research in breast cancer
Publication Type :: Editorial & Opinion
Accession number :: 38751525
Full Text :: https://doi.org/10.21037/tbcr-22-17

Full Text Access

Tools